BCRF is a nonprofit organization committed to achieving prevention and a cure for breast cancer. We provide critical funding for cancer research worldwide to fuel advances in tumor biology, genetics, prevention, treatment, metastasis and survivorship.
Since our founding in 1993 by Evelyn H. Lauder, BCRF has raised more than half a billion dollars for lifesaving research. Through a unique and streamlined grants program, we seek out the brightest minds in science and medicine and give them the necessary resources to pursue their best ideas. As a result, researchers are able to make discoveries and design new approaches to address all aspects of breast cancer—and do so in record time.
“Our goal is to accelerate the breakthroughs bringing us closer to a cure to speed up the progress that will improve survivorship and quality of life for breast cancer patients today.” – Myra J. Biblowit, President & CEO
In 2014-2015, BCRF will award $47 million in annual grants to 222 scientists from top universities and medical institutions around the globe. In addition, $11.6 million has been committed to the international Founder’s Fund project focused on metastasis. Every hour of research we fund improves outcomes and saves lives. But we still have more to do.
The thousands of women and men suffering from breast cancer today depend on us. No institution can conquer this disease alone. Together, we can.
Our mission is to prevent and cure breast cancer by advancing the world's most promising research.
BCRF is recognized as one of the most financially efficient nonprofits in the country. We are the only breast cancer organization with an “A+” from CharityWatch and have a 4-star rating from Charity Navigator.
It all started in 1993 at Evelyn Lauder’s kitchen table.
Over a cup of coffee, Mrs. Lauder and her dear friend Dr. Larry Norton began a conversation that
would, over time, change breast cancer history. Recognizing the power of research and its
potential to change the lives of millions of women and men worldwide, they realized that to
tackle this disease a new approach was critical.